These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 26147471

  • 1. Minimal Prolongation of Prothrombin Time with Extended Exposure to Argatroban.
    McAlister RK, Ito S.
    Pharmacotherapy; 2015 Jul; 35(7):e122-6. PubMed ID: 26147471
    [Abstract] [Full Text] [Related]

  • 2. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
    Bartholomew JR, Hursting MJ.
    J Thromb Thrombolysis; 2005 Jun; 19(3):183-8. PubMed ID: 16082605
    [Abstract] [Full Text] [Related]

  • 3. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.
    Hursting MJ, Lewis BE, Macfarlane DE.
    Clin Appl Thromb Hemost; 2005 Jul; 11(3):279-87. PubMed ID: 16015413
    [Abstract] [Full Text] [Related]

  • 4. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
    Shapiro NL, Durr EA, Krueger CD.
    Pharmacotherapy; 2006 Dec; 26(12):1806-10. PubMed ID: 17125442
    [Abstract] [Full Text] [Related]

  • 5. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy.
    Austin JH, Stearns CR, Winkler AM, Paciullo CA.
    Pharmacotherapy; 2012 Jun; 32(6):493-501. PubMed ID: 22511112
    [Abstract] [Full Text] [Related]

  • 6. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
    Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban-915 Investigators.
    Arch Intern Med; 2012 Jun; 163(15):1849-56. PubMed ID: 12912723
    [Abstract] [Full Text] [Related]

  • 7. Intravenous warfarin and heparin-induced thrombocytopenia: making the diagnosis, management, modern monitoring, and multidisciplinary care.
    Burger CF, Schlesinger JJ.
    Ann Pharmacother; 2014 Feb; 48(2):286-91. PubMed ID: 24259642
    [Abstract] [Full Text] [Related]

  • 8. Use of argatroban as a procedural and bridging anticoagulant in a patient undergoing carotid endarterectomy with concomitant atrial fibrillation.
    Nanda MM, Kauflin MJ, Jain PG, Yannetta JC.
    Ann Pharmacother; 2011 Mar; 45(3):e16. PubMed ID: 21386022
    [Abstract] [Full Text] [Related]

  • 9. Concomitant use of argatroban and warfarin during hemodialysis in heparin-induced thrombocytopenia.
    Vianello F, Furian L, Nordio M, Treleani M, Fabris F.
    Hematology; 2015 Jan; 20(1):48-9. PubMed ID: 24580134
    [Abstract] [Full Text] [Related]

  • 10. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use.
    Lubenow N, Selleng S, Wollert HG, Eichler P, Müllejans B, Greinacher A.
    Ann Thorac Surg; 2003 Feb; 75(2):577-9. PubMed ID: 12607680
    [Abstract] [Full Text] [Related]

  • 11. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin.
    Arpino PA, Demirjian Z, Van Cott EM.
    Pharmacotherapy; 2005 Feb; 25(2):157-64. PubMed ID: 15767231
    [Abstract] [Full Text] [Related]

  • 12. Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia.
    Athar U, Husain J, Hudson J, Lynch J, Gajra A.
    Am J Hematol; 2008 Mar; 83(3):245-6. PubMed ID: 17910040
    [Abstract] [Full Text] [Related]

  • 13. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.
    Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK.
    Thromb Haemost; 2001 Mar; 85(3):435-40. PubMed ID: 11307810
    [Abstract] [Full Text] [Related]

  • 14. Argatroban in adult extracorporeal membrane oxygenation.
    Johnston N, Wait M, Huber L.
    J Extra Corpor Technol; 2002 Dec; 34(4):281-4. PubMed ID: 12533066
    [Abstract] [Full Text] [Related]

  • 15. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
    Dager WE, White RH.
    Ann Pharmacother; 2003 Sep; 37(9):1232-6. PubMed ID: 12921505
    [Abstract] [Full Text] [Related]

  • 16. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A, Wallis DE, Hursting MJ, Katz E, Lewis BE.
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [Abstract] [Full Text] [Related]

  • 17. Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit.
    Demma LJ, Paciullo CA, Levy JH.
    J Thorac Cardiovasc Surg; 2012 May; 143(5):1213-8. PubMed ID: 22329977
    [Abstract] [Full Text] [Related]

  • 18. Warfarin initiation and monitoring with clotting factors II, VII, and X.
    Trask AS, Gosselin RC, Diaz JA, Dager WE.
    Ann Pharmacother; 2004 Feb; 38(2):251-6. PubMed ID: 14742761
    [Abstract] [Full Text] [Related]

  • 19. High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations.
    Hellwig TR, Peitz GJ, Gulseth MP.
    Am J Health Syst Pharm; 2012 Mar 15; 69(6):490-5. PubMed ID: 22382479
    [Abstract] [Full Text] [Related]

  • 20. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT.
    Ann Pharmacother; 2005 Oct 15; 39(10):1601-5. PubMed ID: 16131539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.